Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drugs may shield against Alzheimer's, massive global study hints

NCT ID NCT07677865

Prevention Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study analyzes health records from over 2 million adults across five continents to see if GLP-1 receptor agonists (like semaglutide and liraglutide) can lower the risk of developing Alzheimer's disease. It focuses on people aged 40 and older with type 2 diabetes or obesity, comparing those who started a GLP-1 drug to those who started a different diabetes medication. The goal is to resolve conflicting evidence from earlier real-world studies and randomized trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide, liraglutide)
What this could lead to
If this study confirms a protective effect, it could point toward a way to reduce Alzheimer's risk in people with diabetes or obesity.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by unmeasured factors. Previous randomized trials in early Alzheimer's patients did not show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

213,891 people

The number who actually took part.

Started

Jan 2007

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged ≥ 40 years with type 2 diabetes (ICD-10 E11) or obesity (E66) from five EHR-linked cohorts across four continents: Optum Clinformatics (USA), Mass General Brigham Biobank (USA), CPRD Aurum (UK), Swedish National Diabetes Register (Sweden), and Hong Kong Hospital Authority CDARS (Hong Kong SAR)

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age ≥ 40 years * Diagnosis of type 2 diabetes (ICD-10 E11) or obesity (E66) * ≥ 2 years of continuous enrolment in the cohort * Baseline HbA1c \< 10.5% * No prior diagnosis of any neurodegenerative disease * No prior use of any GLP-1RA or DPP-4i Exclusion Criteria: * • Prior diagnosis of Alzheimer's disease or other neurodegenerative diseases * Prior use of GLP-1 receptor agonists or DPP-4 inhibitors * Age \< 40 years * Baseline HbA1c ≥ 10.5% * Less than 2 years of continuous enrolment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder Overweight type 2 diabetes mellitus Alzheimer disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Diabetes mellitus type 2 Obesity / overweight

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.